Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine

Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine

Background: V-306 is a virus-like particle-based vaccine candidate displaying respiratory syncytial virus (RSV) F site II protein mimetics (FsIIm) as an antigenic epitope. Methods: This was a randomized, placebo-controlled, double-blind, dose-escalating, first-in-human study, conducted in 60 women a...

詳細記述

書誌詳細
主要な著者: Isabel Leroux-Roels, Jacques Bruhwyler, Lilli Stergiou, Mark Sumeray, Jasper Joye, Cathy Maes, Paul-Henri Lambert, Geert Leroux-Roels
フォーマット: 論文
言語:English
出版事項: MDPI AG 2023-02-01
シリーズ:Vaccines
主題:
respiratory syncytial virus
RSV
vaccine
phase I
healthy volunteers
safety
オンライン･アクセス:https://www.mdpi.com/2076-393X/11/2/367

インターネット

https://www.mdpi.com/2076-393X/11/2/367

類似資料